Skip to content
TrialScanner

NCT02693067

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Phase 1Unknown statusPVCTLead

Registry record

Lead sponsor
Provectus Biopharmaceuticals, Inc.
Conditions
Neuroendocrine Tumors Metastatic to the Liver
Primary completion
Sep 1, 2021Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02693067 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02693067: A Phase 1 Study of PV-10... | TrialScanner